



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/599,167	09/21/2006	Kimihiro Mabuchi	19461-006US1 548063	5242
26211	7590	03/10/2011	EXAMINER	
FISH & RICHARDSON P.C. (NY)			MENON, KRISHNAN S	
P.O. BOX 1022			ART UNIT	
MINNEAPOLIS, MN 55440-1022			PAPER NUMBER	
			1777	
			NOTIFICATION DATE	
			DELIVERY MODE	
			03/10/2011	
			ELECTRONIC	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/599,167	MABUCHI ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Krishnan S. Menon	1777	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 20 August 2010.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-26 is/are pending in the application.
- 4a) Of the above claim(s) 7-15 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-6 and 16-26 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                       | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

Claims 1-26 are pending as amended 8/20/10 in an RCE, of which claims 7-15 are withdrawn.

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 24 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 24 recites that the bundles comprises 0.5-40% insoluble matter. This recitation does not make any sense. Does this mean that the hollow fiber membrane would have 99.5% to 40% soluble matter in it as well? Soluble in what? Water? One of ordinary skill in the art would think that the hollow fiber membrane bundle would be 100% insoluble matter, and that nothing would leach out in to the blood when it is used. Of course, the bundle may contain preservatives when shipped, which would be washed out before use, but even the preservatives would be a lot less than 40%. If applicant intends to convey that 0.5-40% is in addition to the polysulfone and PVP, then that is not so conveyed in the claim; and even then the claims are indefinite without reciting what the insoluble matter is and what is its significance.

#### ***Claim Rejections - 35 USC § 102***

Claims 1-6 and 16-26 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Shimagaki et al (US 6,103,117)

Claim interpretation: Applicant's claim 1 recite a perm-selective membrane made from polysulfone and polyvinyl pyrrolidone. The remaining limitations of claim 1 describe a measure of how much hydrogen peroxide can be eluted from the membrane.

Shimagaki teaches hollow fiber membranes and apparatus made from polysulfone and PVP – see examples, with about 40 microns thickness, about 33% PVP content. This reference does not explicitly state the amount of hydrogen peroxide that can be eluted from the membrane, or its UV absorbance. However, since the membrane otherwise has the same composition as well as the starting materials, the residual hydrogen peroxide (from PVP starting material) as well as the UV absorbance resulting from it are assumed to be inherently the same as that of the applicant's.

Cross-linked – see column 11, starting at line 42. The PVP is also insolubilized – same molecular weight of PVP, as well as cross-linked.

Claims 18-23 (amendment 1/22/10) recite further limitations on the process of making the product, which is not patentable: “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product

was made by a different process.” In re *Thorpe*, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985).

Claims 24-26: insoluble matter is not defined, but assumed to be PVP, which the reference teaches (or implied) as insolubilized by cross-linking. Burst pressure of not lower than 0.5 MPa is inherent – same or similar product. The standard deviation in thickness is not a patentable element – it is part of the process of making: quality control.

**Argument** that the method of analysis of the residual hydrogen peroxide in the membrane is not taught by the reference is not persuasive. Claim is for a hollow fiber device, which is taught by the reference. The residual hydrogen peroxide – there is no evidence that the reference membrane has residual hydrogen peroxide in an amount more than 5 ppm, or that it will show any more than 5 ppm of hydrogen peroxide when tested using the recited procedure. Applicant has failed to provide any evidence that the reference membrane would have a hydrogen peroxide content of more than 5ppm, or that it would elute more than 10 ppm of PVP. Just because the reference does not explicitly teach of storage stability, it is erroneous to assume that the membrane of the reference would have poor storage stability. Argument that office action makes no arguments why the claimed subject matter is rendered obvious: this is erroneous – the office action has made it very clear that the residual hydrogen peroxide content in the reference membrane would be inherently the same – same composition and starting material. The express, implicit, and inherent disclosures of a prior art reference may be relied upon in the rejection of claims under 35 U.S.C. 102 or 103. “The inherent

Art Unit: 1777

teaching of a prior art reference, a question of fact, arises both in the context of anticipation and obviousness.” In re Napier, 55 F.3d 610, 613, 34 USPQ2d 1782, 1784 (Fed. Cir. 1995) (affirmed a 35 U.S.C. 103 rejection based in part on inherent disclosure in one of the references). See also In re Grasselli, 713 F.2d 731, 739, 218 USPQ 769, 775 (Fed. Cir. 1983). Where applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection. “There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102.” In re Best, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102/103 rejection is appropriate for these types of claims as well as for composition claims.

### ***Response to Arguments***

Applicant's arguments filed 1/22/10 have been fully considered but they are not persuasive.

Arguments are not commensurate in scope with the claims, because the claims do not recite the argued details for making the membrane that would result in the applicant's stated less than 5 ppm peroxide. However, even if included, such process limitations would not overcome the prima facie case of anticipation/obviousness without

secondary evidence that the reference product do not exhibit the claimed features of elution of peroxide.

Applicant's arguments about the comparative examples having high amounts of extractable peroxides would not constitute evidence that the reference hollow fibers would have such extractables. There is no evidence linking the comparative examples to the Shimagaki hollow fibers.

Applicant uses the same PVP as is used by the reference – source such as BASF. Therefore, the starting polymer in Shimagaki also would have low peroxide content as argued. The reference teaches washing the membrane, which would remove any extractables. Thus there is no reason to believe that the Shimagaki hollow fibers would have peroxide content higher than what applicant's membrane would have.

Regarding the comparison of example 6 of Shimagaki with applicant's comparative example 3 is not persuasive. Among other differences, the comparative example 3 uses PVP containing 450 ppm of hydrogen peroxide. See paragraph 0166 of the PG PUB, which states, "In this regard, poly(vinylpyrrolidone) containing 450 ppm of hydrogen peroxide was used". Nowhere in the Shimagaki reference does it suggest using PVP containing 450 ppm hydrogen peroxide. Nor would there be a reason one of ordinary skill in the art would think that Shimgaki could be using PVP of high hydrogen peroxide content. On the contrary, one of ordinary skill in the art would only consider using the purest form of materials available in the market for making such membranes because they are intended for medical applications.

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Krishnan S. Menon whose telephone number is 571-272-1143. The examiner can normally be reached on 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vickie Kim can be reached on 571-272-0579. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Krishnan S Menon/  
Primary Examiner, Art Unit 1797